Literature DB >> 12967055

Patients with Alzheimer's disease living at home in France: costs and consequences of the disease.

Anne-Sophie Rigaud1, Francis Fagnani, Catherine Bayle, Florence Latour, Latchezar Traykov, Françoise Forette.   

Abstract

Alzheimer's disease (AD) creates a substantial burden on human and financial resources. However, there are few data relating to the cost of AD in France. This retrospective study assesses the total costs of caring for home-based patients with mild to moderate AD. Pattern of care, sociodemographic data, caregiver burden, and estimated net costs of caring for AD patients were assessed in a stratified sample of 50 untreated AD patients. The net costs of caring for all AD patients who completed all study parameters increased with decreasing cognitive ability. Unpaid assistance was the most costly component of the total cost of care. Mini-Mental State Examination scores correlated strongly with functional status, and instrumental activities of daily living scores were a robust indicator of the magnitude of behavioral, cognitive, and dependence problems. This study suggested a significant link between costs of caring for an AD patient at home and disease severity.

Entities:  

Mesh:

Year:  2003        PMID: 12967055     DOI: 10.1177/0891988703252558

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  16 in total

Review 1.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.

Authors:  Jaclyn Cappell; Nathan Herrmann; Stephen Cornish; Krista L Lanctôt
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Implications of the Impact Survey for payors across Europe.

Authors:  F Forette; A Padovani; K Berthet; S Knox
Journal:  J Nutr Health Aging       Date:  2010-08       Impact factor: 4.075

5.  Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial.

Authors:  Bernhard Michalowsky; Steffen Flessa; Tilly Eichler; Johannes Hertel; Adina Dreier; Ina Zwingmann; Diana Wucherer; Henriette Rau; Jochen René Thyrian; Wolfgang Hoffmann
Journal:  Eur J Health Econ       Date:  2017-02-03

6.  Costs of dementia in the Czech Republic.

Authors:  Iva Holmerová; Jakub Hort; Robert Rusina; Anders Wimo; Michal Šteffl
Journal:  Eur J Health Econ       Date:  2016-10-26

7.  Economic valuation and determinants of informal care to people with Alzheimer's disease.

Authors:  Luz María Peña-Longobardo; Juan Oliva-Moreno
Journal:  Eur J Health Econ       Date:  2014-05-07

8.  Substitute consent for research involving the elderly: a comparison between Quebec and France.

Authors:  Gina Bravo; Anne-Marie Duguet; Marie-France Dubois; Cyrille Delpierre; Bruno Vellas
Journal:  J Cross Cult Gerontol       Date:  2008-09

Review 9.  The cost of dementia in Europe: a review of the evidence, and methodological considerations.

Authors:  Linus Jönsson; Anders Wimo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Methodological considerations in cost of illness studies on Alzheimer disease.

Authors:  Nagede Costa; Helene Derumeaux; Thomas Rapp; Valérie Garnault; Laura Ferlicoq; Sophie Gillette; Sandrine Andrieu; Bruno Vellas; Michel Lamure; Alain Grand; Laurent Molinier
Journal:  Health Econ Rev       Date:  2012-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.